Bayer AG Standardizes on ³Ô¹Ï±¬ÁÏ Vault Clinical Applications Globally
Global life sciences leader selects Vault Study Startup and Vault eTMF to improve trial efficiency
PLEASANTON, CA ¡ª July 22, 2020 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE:VEEV) today announced that Bayer AG (ETR:BAYN) has selected ³Ô¹Ï±¬ÁÏ Vault Study Startup and ³Ô¹Ï±¬ÁÏ Vault eTMF globally to accelerate site activation and improve visibility across trials.
"³Ô¹Ï±¬ÁÏ cloud applications will enable us to streamline trial execution,¡± said Joerg Moeller, Head of Pharma R&D at Bayer AG. ¡°We appreciate ³Ô¹Ï±¬ÁÏ¡¯s modern technology and customer-centric approach to partnership.¡±
³Ô¹Ï±¬ÁÏ will enable Bayer AG to manage clinical content and data on a single cloud platform to unify their operations. Vault Study Startup streamlines end-to-end study start-up processes from site identification to site greenlight. Vault eTMF enables active TMF management for real-time visibility and control, helping life sciences companies meet compliance regulations to stay inspection ready.
Bringing both these applications together will enable Bayer AG¡¯s clinical teams to eliminate manual processes, share the same trial documents, and automatically file content from Vault Study Startup in Vault eTMF.
¡°Life sciences companies are adopting ³Ô¹Ï±¬ÁÏ Vault Clinical applications to speed study execution as they manage a growing number of clinical trials,¡± said Rik Van Mol, vice president of strategy for ³Ô¹Ï±¬ÁÏ Development Cloud. ¡°Now Bayer AG will be able to have a complete view of trial documents from study activation to study close, while maintaining a constant state of inspection readiness.¡±
Vault Study Startup and Vault eTMF are part of the ³Ô¹Ï±¬ÁÏ Vault Clinical Suite, the industry¡¯s first cloud platform that includes CDMS, Study Startup, eTMF, CTMS, and Payments to unify clinical data management and clinical operations. ³Ô¹Ï±¬ÁÏ¡¯s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes.
Learn more about ³Ô¹Ï±¬ÁÏ Vault Clinical Suite at the upcoming ³Ô¹Ï±¬ÁÏ R&D and Quality Summit, October 13-14, 2020. The virtual event is only open to life sciences industry professionals. Register and stay up-to-date on program details at veeva.com/R&DSummit. Also, watch the on-demand presentations from ³Ô¹Ï±¬ÁÏ R&D and Quality Summit, Europe at veeva.com/EUSummit.
Additional Information
For more on ³Ô¹Ï±¬ÁÏ Vault Clinical Suite, visit: veeva.com/Clinical
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.
###
Contact:
³Ô¹Ï±¬ÁÏ Systems
pr@veeva.com
Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-452-6500
deivis.mercado@veeva.com